TMDX LEGAL DEADLINE: TransMedics Group Investors that Lost Money are Reminded of Pending Class Action – Contact BFA Law by April 15 Court Deadline (NASDAQ:TMDX)

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics misrepresented its business practices, claiming they were driven by kickbacks, fraudulent overbilling, and coercive tactics [4]. - It is further alleged that the company engaged in unsafe practices involving OCS, concealed safety issues, and lacked proper safety oversight [4]. Group 4: Stock Performance - Following allegations of misconduct from U.S. Representative Paul Gosar, TransMedics' stock price fell approximately 4%, from $86.99 on February 21, 2024, to$83.14 on February 23, 2024 [5]. - After a report from Scorpion Capital on January 10, 2025, which accused TransMedics of anti-competitive schemes and billing fraud, the stock price declined an additional 5%, from $72.55 on January 8, 2025, to$68.81 on January 10, 2025 [6].